Literature DB >> 27182819

Vaccination evokes gender-dependent protection against tularemia infection in C57BL/6Tac mice.

Raju Sunagar1, Sudeep Kumar1, Brian J Franz1, Edmund J Gosselin2.   

Abstract

Francisella tularensis (Ft) is a Category A biothreat agent for which there currently is no FDA-approved vaccine. Thus, there is a substantial effort underway to develop an effective tularemia vaccine. While it is well established that gender can significantly impact susceptibility to primary infection, the impact of gender on vaccine efficacy is not well established. Thus, development of a successful vaccine against tularemia will require an understanding of the impact gender has on vaccine-induced protection against this organism. In this study, a role for gender in vaccine-induced protection following Ft challenge is identified for the first time. In the present study, mucosal vaccination with inactivated Ft (iFt) LVS elicited gender-based protection in C57BL/6Tac mice against respiratory challenge with Ft LVS. Specifically, vaccinated male mice were more susceptible to subsequent Ft LVS challenge. This increased susceptibility in male mice correlated with increased bacterial burden, increased tissue inflammation, and increased proinflammatory cytokine production late in post-challenge infection. In contrast, improved survival of iFt-vaccinated female mice correlated with reduced bacterial burden and enhanced levels of Ft-specific Abs in serum and broncho-alveolar lavage (BAL) fluid post-challenge. Furthermore, vaccination with a live attenuated vaccine consisting of an Ft LVS superoxide dismutase (SodB) mutant, which has proven efficacious against the highly virulent Ft SchuS4 strain, demonstrated similar gender bias in protection post-Ft SchuS4 challenge. Of particular significance is the fact that these are the first studies to demonstrate that gender differences impact disease outcome in the case of lethal respiratory tularemia following mucosal vaccination. In addition, these studies further emphasize the fact that gender differences must be a serious consideration in any future tularemia vaccine development studies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gender differences; Host susceptibility; Humoral immunity; Inactivated vaccine; Intranasal vaccine; Proinflammatory cytokines; Tularemia

Mesh:

Substances:

Year:  2016        PMID: 27182819      PMCID: PMC4905791          DOI: 10.1016/j.vaccine.2016.04.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens.

Authors:  Félix Gutiérrez; Mar Masiá; Carlos Mirete; Bernardo Soldán; J Carlos Rodríguez; Sergio Padilla; Ildefonso Hernández; Gloria Royo; Alberto Martin-Hidalgo
Journal:  J Infect       Date:  2006-01-10       Impact factor: 6.072

2.  Epidemiology and clinical characteristics of tularemia in Oklahoma, 1979 to 1985.

Authors:  B W Rohrbach; E Westerman; G R Istre
Journal:  South Med J       Date:  1991-09       Impact factor: 0.954

3.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

4.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

5.  The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.

Authors:  Timothy L Wiemken; Ruth M Carrico; Sabra L Klein; Colleen B Jonsson; Paula Peyrani; Robert R Kelley; Stefano Aliberti; Francesco Blasi; Ricardo Fernandez-Gonzalez; Gustavo Lopardo; Julio A Ramirez
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

6.  The relationship of gender and in-hospital death: increased risk of death in men.

Authors:  H S Gordon; G E Rosenthal
Journal:  Med Care       Date:  1999-03       Impact factor: 2.983

7.  Male gender is a risk factor for major infections after surgery.

Authors:  P J Offner; E E Moore; W L Biffl
Journal:  Arch Surg       Date:  1999-09

8.  Gender difference in cytokine secretion on immune stimulation with LPS and LTA.

Authors:  Sonja Von Aulock; Susanne Deininger; Christian Draing; Katja Gueinzius; Oliver Dehus; Corinna Hermann
Journal:  J Interferon Cytokine Res       Date:  2006-12       Impact factor: 2.607

9.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

10.  Sexual dimorphism in immune response genes as a function of puberty.

Authors:  Rebecca Lamason; Po Zhao; Rashmi Rawat; Adrian Davis; John C Hall; Jae Jin Chae; Rajeev Agarwal; Phillip Cohen; Antony Rosen; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  BMC Immunol       Date:  2006-02-22       Impact factor: 3.615

View more
  5 in total

1.  Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.

Authors:  Alison A McCormick; Aisha Shakeel; Chris Yi; Hardeep Kaur; Ahd M Mansour; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

2.  Evaluation of an outbred mouse model for Francisella tularensis vaccine development and testing.

Authors:  Raju Sunagar; Sudeep Kumar; Prachi Namjoshi; Sarah J Rosa; Karsten R O Hazlett; Edmund J Gosselin
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

3.  Murine macrophage TLR2-FcγR synergy via FcγR licensing of IL-6 cytokine mRNA ribosome binding and translation.

Authors:  Danielle Hunt; Lisa A Drake; James R Drake
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

4.  Cross Sectional Study and Risk Factors Analysis of Francisella tularensis in Soil Samples in Punjab Province of Pakistan.

Authors:  Javed Muhammad; Masood Rabbani; Muhammad Zubair Shabbir; Khushi Muhammad; Muhammad Taslim Ghori; Haroon Rashid Chaudhry; Zia Ul Hassnain; Tariq Jamil; Tariq Abbas; Muhammad Hamid Chaudhry; Muhammad Haisem-Ur-Rasool; Muhammad Asad Ali; Muhammad Nisar; Girish S Kirimanjeswara; Bhushan M Jayarao
Journal:  Front Cell Infect Microbiol       Date:  2019-04-05       Impact factor: 5.293

5.  Differential In Vitro Cultivation of Francisella tularensis Influences Live Vaccine Protective Efficacy by Altering the Immune Response.

Authors:  Raju Sunagar; Sudeep Kumar; Sarah J Rosa; Karsten R O Hazlett; Edmund J Gosselin
Journal:  Front Immunol       Date:  2018-07-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.